2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one has been researched along with Lung Neoplasms in 88 studies
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gefitinib resistance remains a major problem in the treatment of lung adenocarcinoma." | 7.83 | FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop. ( Li, Y; Liu, W; Luo, E; Tian, L; Wang, Y; Wen, L; Wen, M; Wen, N; Yang, H; Yun, Y; Zhang, W; Zhao, L; Zhu, X, 2016) |
| "Gefitinib resistance remains a major problem in the treatment of lung adenocarcinoma." | 3.83 | FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop. ( Li, Y; Liu, W; Luo, E; Tian, L; Wang, Y; Wen, L; Wen, M; Wen, N; Yang, H; Yun, Y; Zhang, W; Zhao, L; Zhu, X, 2016) |
| "Cotylenin A, a plant growth regulator, and rapa-mycin, an inhibitor of the mammalian target of rapamycin, are potent inducers of differentiation in myeloid leukemia cells and also synergistically inhibit the proliferation of several human breast cancer cell lines including MCF-7 in vitro and in vivo." | 3.79 | Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells. ( Haranosono, Y; Honma, Y; Kasukabe, T; Kato, N; Okabe-Kado, J, 2013) |
| "Treatment with sesamin caused cell cycle arrest at G1 phase and inhibited cyclin D1 and CDK2 expression." | 1.56 | Sesamin suppresses NSCLC cell proliferation and induces apoptosis via Akt/p53 pathway. ( Chen, Y; Huang, H; Li, H; Liu, B; Lu, C; Qi, W; Yang, Z; Zhang, L; Zhang, W, 2020) |
| " The present study investigated the effect of hydrogen‑rich saline alone and in combination with the PI3K inhibitor, LY294002, on the proliferation, oxidative stress and apoptosis of NSCLC A549 cells." | 1.48 | Therapeutic efficacy of hydrogen‑rich saline alone and in combination with PI3K inhibitor in non‑small cell lung cancer. ( Cheng, S; Guo, S; Jiang, Y; Liao, Y; Liu, G; Luo, C; Zhang, L, 2018) |
| " Besides, xenograft experiment showed that combination with autophagy inhibitor potentiated the anti-tumor efficacy of rhArg in vivo." | 1.46 | A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor. ( Cao, Z; Fan, J; Fu, X; Ju, D; Luan, J; Shen, W; Xu, Z; Yang, P; Zhang, X, 2017) |
| "Lung cancer is the most common cause of cancer‑associated mortality worldwide, and glucosamine has the potential to exhibit antitumor activity." | 1.46 | Anti‑lung cancer effect of glucosamine by suppressing the phosphorylation of FOXO. ( Ju, Y; Liu, H; Yu, Z, 2017) |
| " The effects of ospemifene (OSP) on the immune response to a peptide cancer vaccine (PV) were evaluated after chronic [control (n = 22); OSP 50 mg/kg (n = 16); PV (n = 6); OSP+PV (n = 11)], intermittent [control (n = 10); OSP 10 and 50 mg/kg (n = 11); PV (n = 11); combination treatment (n = 11 each dose)] and pretreatment [control; OSP 100 mg/kg; PV 100 μg; combination treatment (n = 8 all groups)] ospemifene oral dosing schedules in a total of 317 mixed-sex tumor-bearing and nontumor-bearing mice." | 1.46 | Repurposing ospemifene for potentiating an antigen-specific immune response. ( DeGregorio, MW; Kao, CJ; Lin, YC; Phong, B; Vang, DP; Wurz, GT, 2017) |
| "Metastases are the primary cause of human cancer deaths." | 1.39 | Raf and PI3K are the molecular targets for the anti-metastatic effect of luteolin. ( Byun, S; Heo, YS; Jung, SK; Kang, MJ; Kim, HY; Lee, HJ; Lee, J; Lee, KW; Oh, MH; Son, JE, 2013) |
| " The objective of this study was to evaluate the effect of various SPI, both alone and in combination with cisplatin, on three different non-small cell lung cancer (NSCLC) cell lines." | 1.35 | Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines. ( El-Hefnawy, T; Kilic, A; Landreneau, RJ; Luketich, JD; Schuchert, MJ, 2009) |
| "Human pulmonary carcinoid NCI-H727 cells were treated with LY294002 (0 to 100 microM), a well-known PI3K inhibitor, or transfected with Akt1 small interfering RNA (75 nM)." | 1.35 | Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells. ( Chen, H; Kunnimalaiyaan, M; Pitt, SC, 2009) |
| "In the breast cancer model (MCF10A/MCF7) and lung cancer model (BEAS/H1198/H1170) we also found the same result: PRAS40 was constitutively active in H1198/H1170 and MCF7 pre-malignant and malignant cancer cells, but weakly expressed in MCF10A and BEAS normal cell." | 1.33 | Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis. ( Huang, B; Porter, G, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.27) | 18.2507 |
| 2000's | 40 (45.45) | 29.6817 |
| 2010's | 41 (46.59) | 24.3611 |
| 2020's | 5 (5.68) | 2.80 |
| Authors | Studies |
|---|---|
| Ryu, BJ | 1 |
| Hwang, MK | 1 |
| Park, M | 1 |
| Lee, K | 1 |
| Kim, SH | 2 |
| Chen, Y | 2 |
| Li, H | 4 |
| Zhang, W | 3 |
| Qi, W | 1 |
| Lu, C | 2 |
| Huang, H | 1 |
| Yang, Z | 1 |
| Liu, B | 2 |
| Zhang, L | 3 |
| Sun, Y | 1 |
| Zhang, Z | 2 |
| Xiang, F | 1 |
| Zhang, M | 2 |
| Chen, Q | 2 |
| Tang, L | 1 |
| Zhu, L | 2 |
| Liu, J | 1 |
| Meng, Z | 1 |
| Hu, J | 2 |
| Luo, X | 1 |
| Ni, Z | 1 |
| Wang, X | 6 |
| Wang, J | 2 |
| Liu, X | 1 |
| Zheng, H | 1 |
| Liu, Q | 1 |
| Zhang, H | 1 |
| Shen, T | 1 |
| Wang, S | 2 |
| Ren, D | 1 |
| Sun, T | 2 |
| Zhang, J | 3 |
| Deng, B | 1 |
| Fan, X | 1 |
| Long, T | 1 |
| Jin, H | 1 |
| Tao, S | 1 |
| Kang, P | 1 |
| Tan, Q | 1 |
| Chen, JC | 1 |
| Ko, JC | 1 |
| Taso, YC | 1 |
| Cheng, HH | 1 |
| Chen, TY | 1 |
| Yen, TC | 1 |
| Lin, YW | 1 |
| Shen, W | 1 |
| Zhang, X | 3 |
| Fu, X | 1 |
| Fan, J | 1 |
| Luan, J | 1 |
| Cao, Z | 1 |
| Yang, P | 1 |
| Xu, Z | 3 |
| Ju, D | 1 |
| Yan, Y | 1 |
| Xiao, L | 1 |
| Dai, S | 1 |
| Zeng, S | 1 |
| Qian, L | 1 |
| Wang, L | 1 |
| Yang, X | 2 |
| Xiao, Y | 1 |
| Gong, Z | 1 |
| Yu, Z | 1 |
| Ju, Y | 1 |
| Liu, H | 2 |
| Lin, J | 1 |
| Liu, R | 1 |
| Miao, K | 1 |
| Shou, T | 1 |
| Jiang, Y | 1 |
| Liu, G | 1 |
| Cheng, S | 1 |
| Luo, C | 1 |
| Liao, Y | 1 |
| Guo, S | 1 |
| Baruah, TJ | 1 |
| Kma, L | 1 |
| Liu, L | 1 |
| Zhou, XY | 1 |
| Zhang, JQ | 1 |
| Wang, GG | 1 |
| He, J | 2 |
| Chen, YY | 1 |
| Huang, C | 1 |
| Li, L | 2 |
| Li, SQ | 1 |
| Luo, Y | 1 |
| Ren, Z | 1 |
| Du, B | 2 |
| Xing, S | 1 |
| Huang, S | 2 |
| Li, Y | 4 |
| Lei, Z | 1 |
| Li, D | 1 |
| Chen, H | 3 |
| Huang, Y | 1 |
| Wei, G | 1 |
| Diao, Y | 1 |
| Li, X | 1 |
| Chen, S | 1 |
| Wang, Y | 2 |
| Chen, L | 1 |
| Huang, G | 1 |
| He, D | 1 |
| Xu, W | 2 |
| Zou, C | 1 |
| Zong, F | 1 |
| Chen, B | 1 |
| Wu, S | 1 |
| Zhao, W | 1 |
| Wu, J | 1 |
| Wang, YL | 1 |
| Zhu, BJ | 1 |
| Qi, ZZ | 1 |
| Wang, HJ | 1 |
| Zhou, XD | 1 |
| Liu, D | 1 |
| Fan, C | 1 |
| Luan, L | 1 |
| Wang, E | 1 |
| Badinloo, M | 1 |
| Esmaeili-Mahani, S | 1 |
| Shats, I | 1 |
| Gatza, ML | 1 |
| Angus, SP | 1 |
| You, L | 1 |
| Nevins, JR | 1 |
| Mango, RL | 1 |
| Wu, QP | 1 |
| West, M | 1 |
| McCook, EC | 1 |
| Serody, JS | 1 |
| van Deventer, HW | 1 |
| Xu, Y | 1 |
| Jiang, Z | 1 |
| Sun, N | 1 |
| Xie, J | 1 |
| Li, T | 1 |
| Hou, Y | 1 |
| Wu, D | 1 |
| Ito, S | 1 |
| Igishi, T | 2 |
| Takata, M | 1 |
| Ueda, Y | 1 |
| Matsumoto, S | 1 |
| Kodani, M | 2 |
| Takeda, K | 2 |
| Izumi, H | 1 |
| Sakamoto, T | 1 |
| Yamaguchi, K | 1 |
| Makino, H | 1 |
| Touge, H | 1 |
| Chikumi, H | 1 |
| Shimizu, E | 2 |
| Ning, J | 1 |
| Liu, W | 2 |
| Lang, Y | 1 |
| Xu, S | 1 |
| Jin, Q | 1 |
| Lee, HJ | 2 |
| Min, HY | 1 |
| Smith, JK | 1 |
| Hwang, SJ | 1 |
| Whang, YM | 1 |
| Kim, WY | 1 |
| Kim, YH | 1 |
| Lee, HY | 2 |
| Porcelli, L | 1 |
| Giovannetti, E | 2 |
| Assaraf, YG | 1 |
| Jansen, G | 1 |
| Scheffer, GL | 1 |
| Kathman, I | 1 |
| Azzariti, A | 1 |
| Paradiso, A | 1 |
| Peters, GJ | 2 |
| Wang, Z | 1 |
| Lin, Y | 1 |
| Chen, Z | 2 |
| Wang, N | 1 |
| Song, X | 1 |
| Yang, Y | 2 |
| Xu, H | 1 |
| Huang, W | 1 |
| Ding, M | 1 |
| Xiao, J | 1 |
| Yang, D | 1 |
| Liu, XY | 1 |
| Chu, L | 1 |
| Sonoki, H | 1 |
| Sato, T | 1 |
| Endo, S | 3 |
| Matsunaga, T | 3 |
| Yamaguchi, M | 2 |
| Yamazaki, Y | 2 |
| Sugatani, J | 2 |
| Ikari, A | 3 |
| Yang, J | 1 |
| Qin, G | 1 |
| Luo, M | 1 |
| Chen, J | 1 |
| Zhang, Q | 1 |
| Pan, L | 1 |
| Qin, S | 1 |
| Lim, HS | 1 |
| Kang, YJ | 1 |
| Sung, B | 1 |
| Kim, MJ | 1 |
| Kim, HR | 2 |
| Kim, SJ | 1 |
| Choi, YH | 2 |
| Moon, HR | 1 |
| Chung, HY | 1 |
| Kim, ND | 1 |
| Liu, Y | 1 |
| Fei, T | 1 |
| Zheng, X | 1 |
| Brown, M | 1 |
| Zhang, P | 1 |
| Liu, XS | 1 |
| Wang, H | 1 |
| Shimobaba, S | 1 |
| Taga, S | 2 |
| Akizuki, R | 2 |
| Hichino, A | 2 |
| Watanabe, R | 1 |
| Wen, L | 1 |
| Yang, H | 1 |
| Wen, M | 1 |
| Yun, Y | 1 |
| Zhao, L | 1 |
| Zhu, X | 2 |
| Tian, L | 1 |
| Luo, E | 1 |
| Wen, N | 1 |
| Kao, CJ | 1 |
| Wurz, GT | 1 |
| Lin, YC | 1 |
| Vang, DP | 1 |
| Phong, B | 1 |
| DeGregorio, MW | 1 |
| Jeon, YK | 1 |
| Kim, CK | 1 |
| Hwang, KR | 1 |
| Park, HY | 1 |
| Koh, J | 1 |
| Chung, DH | 1 |
| Lee, CW | 1 |
| Ha, GH | 1 |
| Okamoto, M | 1 |
| Riedel, RF | 1 |
| Porrello, A | 1 |
| Pontzer, E | 1 |
| Chenette, EJ | 1 |
| Hsu, DS | 1 |
| Balakumaran, B | 1 |
| Potti, A | 1 |
| Nevins, J | 1 |
| Febbo, PG | 1 |
| Fong, YC | 2 |
| Liu, SC | 1 |
| Huang, CY | 2 |
| Li, TM | 1 |
| Hsu, SF | 1 |
| Kao, ST | 1 |
| Tsai, FJ | 1 |
| Chen, WC | 1 |
| Chen, CY | 1 |
| Tang, CH | 2 |
| Kikuchi, J | 1 |
| Kinoshita, I | 1 |
| Shimizu, Y | 1 |
| Oizumi, S | 1 |
| Nishimura, M | 1 |
| Birrer, MJ | 1 |
| Dosaka-Akita, H | 1 |
| Lee, CY | 1 |
| Chen, MY | 1 |
| Tsai, HC | 1 |
| Hsu, HC | 1 |
| Kilic, A | 1 |
| Schuchert, MJ | 1 |
| Luketich, JD | 1 |
| Landreneau, RJ | 1 |
| El-Hefnawy, T | 1 |
| Qian, J | 1 |
| Zou, Y | 1 |
| Rahman, JS | 1 |
| Lu, B | 1 |
| Massion, PP | 1 |
| Deng, QF | 1 |
| Su, B | 2 |
| Zhao, YM | 1 |
| Zhou, CC | 1 |
| Purnell, PR | 1 |
| Mack, PC | 1 |
| Tepper, CG | 1 |
| Evans, CP | 1 |
| Green, TP | 1 |
| Gumerlock, PH | 1 |
| Lara, PN | 1 |
| Gandara, DR | 1 |
| Kung, HJ | 1 |
| Gautschi, O | 1 |
| Park, SC | 1 |
| Yoo, HS | 1 |
| Park, C | 1 |
| Cho, CK | 1 |
| Kim, GY | 1 |
| Kim, WJ | 1 |
| Lee, YW | 1 |
| Cortes-Sempere, M | 1 |
| Chattopadhyay, S | 1 |
| Rovira, A | 1 |
| Rodriguez-Fanjul, V | 1 |
| Belda-Iniesta, C | 1 |
| Tapia, M | 1 |
| Cejas, P | 1 |
| Machado-Pinilla, R | 1 |
| Manguan-García, C | 1 |
| Sánchez-Pérez, I | 1 |
| Nistal, M | 1 |
| Moratilla, C | 1 |
| de Castro-Carpeño, J | 1 |
| Gonzalez-Barón, M | 1 |
| Albanell, J | 1 |
| Perona, R | 1 |
| Kelly-Spratt, KS | 1 |
| Philipp-Staheli, J | 1 |
| Gurley, KE | 1 |
| Hoon-Kim, K | 1 |
| Knoblaugh, S | 1 |
| Kemp, CJ | 1 |
| Pitt, SC | 1 |
| Kunnimalaiyaan, M | 1 |
| Matsumoto, K | 1 |
| Arao, T | 1 |
| Tanaka, K | 1 |
| Kaneda, H | 1 |
| Kudo, K | 1 |
| Fujita, Y | 1 |
| Tamura, D | 1 |
| Aomatsu, K | 1 |
| Tamura, T | 1 |
| Yamada, Y | 1 |
| Saijo, N | 1 |
| Nishio, K | 1 |
| Hwang, KE | 1 |
| Na, KS | 1 |
| Park, DS | 1 |
| Choi, KH | 1 |
| Kim, BR | 1 |
| Shim, H | 1 |
| Jeong, ET | 1 |
| Petersen, SL | 1 |
| Peyton, M | 1 |
| Minna, JD | 1 |
| Zhang, C | 1 |
| Elkahloun, AG | 1 |
| Liao, H | 1 |
| Delaney, S | 1 |
| Saber, B | 1 |
| Morrow, B | 1 |
| Prendergast, GC | 1 |
| Hollander, MC | 1 |
| Gills, JJ | 2 |
| Dennis, PA | 3 |
| Reka, AK | 1 |
| Kuick, R | 1 |
| Kurapati, H | 1 |
| Standiford, TJ | 1 |
| Omenn, GS | 1 |
| Keshamouni, VG | 1 |
| Schmid-Bindert, G | 1 |
| Wang, D | 1 |
| Zhao, Y | 2 |
| Zhou, C | 1 |
| Long, L | 1 |
| Hui, L | 1 |
| Shen, H | 1 |
| Kim, HY | 1 |
| Jung, SK | 1 |
| Byun, S | 1 |
| Son, JE | 1 |
| Oh, MH | 1 |
| Lee, J | 1 |
| Kang, MJ | 1 |
| Heo, YS | 1 |
| Lee, KW | 1 |
| Han, R | 1 |
| Zhong, D | 1 |
| Zhao, J | 1 |
| Sun, L | 1 |
| Kasukabe, T | 1 |
| Okabe-Kado, J | 1 |
| Haranosono, Y | 1 |
| Kato, N | 1 |
| Honma, Y | 1 |
| Kodama, Y | 1 |
| Baxter, RC | 1 |
| Martin, JL | 1 |
| Kijima, T | 2 |
| Maulik, G | 1 |
| Ma, PC | 1 |
| Tibaldi, EV | 1 |
| Turner, RE | 1 |
| Rollins, B | 1 |
| Sattler, M | 1 |
| Johnson, BE | 1 |
| Salgia, R | 1 |
| Krystal, GW | 1 |
| Sulanke, G | 1 |
| Litz, J | 1 |
| Cordes, N | 1 |
| van Beuningen, D | 1 |
| Piccolo, E | 1 |
| Vignati, S | 1 |
| Maffucci, T | 1 |
| Innominato, PF | 1 |
| Riley, AM | 1 |
| Potter, BV | 1 |
| Pandolfi, PP | 1 |
| Broggini, M | 1 |
| Iacobelli, S | 1 |
| Innocenti, P | 1 |
| Falasca, M | 1 |
| You, H | 1 |
| Wei, L | 1 |
| Yao, L | 1 |
| Fan, D | 1 |
| Yu, Q | 1 |
| Nguyen, DM | 1 |
| Chen, GA | 1 |
| Reddy, R | 1 |
| Tsai, W | 1 |
| Schrump, WD | 1 |
| Cole, G | 1 |
| Schrump, DS | 1 |
| Sun, SY | 1 |
| Rosenberg, LM | 1 |
| Zhou, Z | 1 |
| Yue, P | 1 |
| Fu, H | 1 |
| Khuri, FR | 1 |
| Oh, SH | 1 |
| Suh, YA | 1 |
| Baek, JH | 1 |
| Papadimitrakopoulou, V | 1 |
| Hong, WK | 1 |
| Fukaya, Y | 1 |
| Ishiguro, N | 1 |
| Senga, T | 1 |
| Ichigotani, Y | 1 |
| Sohara, Y | 1 |
| Tsutsui, M | 1 |
| Shioura, T | 1 |
| Iwamoto, T | 1 |
| Hamaguchi, M | 1 |
| Tsurutani, J | 1 |
| West, KA | 1 |
| Sayyah, J | 1 |
| Chen, PN | 1 |
| Hsieh, YS | 1 |
| Chiou, HL | 1 |
| Chu, SC | 1 |
| Huang, B | 1 |
| Porter, G | 1 |
| Denlinger, CE | 1 |
| Rundall, BK | 1 |
| Jones, DR | 1 |
| Coffey, JC | 1 |
| Wang, JH | 1 |
| Bouchier-Hayes, D | 1 |
| Cotter, TG | 1 |
| Redmond, HP | 1 |
| Hemström, TH | 1 |
| Sandström, M | 1 |
| Zhivotovsky, B | 1 |
| Ohnishi, K | 1 |
| Yasumoto, J | 1 |
| Takahashi, A | 1 |
| Ohnishi, T | 1 |
| Uemura, Y | 1 |
| Kobayashi, M | 1 |
| Nakata, H | 1 |
| Kubota, T | 1 |
| Bandobashi, K | 1 |
| Saito, T | 1 |
| Taguchi, H | 1 |
| Ogata, Y | 1 |
| Osaki, T | 1 |
| Naka, T | 1 |
| Iwahori, K | 1 |
| Furukawa, M | 1 |
| Nagatomo, I | 1 |
| Kumagai, T | 1 |
| Yoshida, M | 1 |
| Tachibana, I | 1 |
| Kawase, I | 1 |
| Morita, M | 1 |
| Suyama, H | 1 |
| Shigeoka, Y | 1 |
| Hashimoto, K | 1 |
| Sumikawa, T | 1 |
| Furuya, F | 1 |
| Willingham, MC | 1 |
| Cheng, SY | 1 |
| Lemos, C | 1 |
| Tekle, C | 1 |
| Smid, K | 1 |
| Nannizzi, S | 1 |
| Rodriguez, JA | 1 |
| Ricciardi, S | 1 |
| Danesi, R | 1 |
| Giaccone, G | 1 |
| Sos, ML | 1 |
| Zander, T | 1 |
| Thomas, RK | 1 |
| Staratschek-Jox, A | 1 |
| Claasen, J | 1 |
| Wolf, J | 1 |
| Jia, L | 1 |
| Yu, W | 1 |
| Wang, P | 1 |
| Sanders, BG | 1 |
| Kline, K | 1 |
| Park, JK | 1 |
| Jung, HY | 1 |
| Park, SH | 1 |
| Kang, SY | 1 |
| Yi, MR | 1 |
| Um, HD | 1 |
| Hong, SH | 1 |
| Dhar, R | 1 |
| Basu, A | 1 |
| Moore, SM | 1 |
| Rintoul, RC | 1 |
| Walker, TR | 1 |
| Chilvers, ER | 1 |
| Haslett, C | 1 |
| Sethi, T | 1 |
| Pan, ZK | 1 |
| Christiansen, SC | 1 |
| Ptasznik, A | 1 |
| Zuraw, BL | 1 |
| Brognard, J | 1 |
| Clark, AS | 1 |
| Ni, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies[NCT00770263] | Phase 1 | 46 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Neoadjuvant Icotinib With Chemotherapy for Resectable Stage II-IIIB N2 EGFR Mutation-positive Lung Adenocarcinoma: A Phase II Study[NCT05132985] | Phase 2 | 45 participants (Anticipated) | Interventional | 2022-01-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
88 other studies available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Lung Neoplasms
| Article | Year |
|---|---|
Thiourea compound AW00178 sensitizes human H1299 lung carcinoma cells to TRAIL-mediated apoptosis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Res | 2012 |
Sesamin suppresses NSCLC cell proliferation and induces apoptosis via Akt/p53 pathway.
Topics: Animals; Apoptosis; Benzothiazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Prolifera | 2020 |
Decreasing Arl4c expression by inhibition of AKT signal in human lung adenocarcinoma cells.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; ADP-Ribosylation Factors; Blotting, Western; Cam | 2020 |
Morusin induces apoptosis and autophagy via JNK, ERK and PI3K/Akt signaling in human lung carcinoma cells.
Topics: Apoptosis; Autophagy; Caspase 3; Cell Line, Tumor; Cell Proliferation; Chromones; Extracellular Sign | 2020 |
FOXO1 and FOXO3a sensitize non-small-cell lung cancer cells to cisplatin-induced apoptosis independent of Bim.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Ce | 2020 |
Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzoquinones; Bevacizumab; Carcinoma, Non-Small-Cel | 2021 |
A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor.
Topics: Apoptosis; Arginase; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chloroquine; Chrom | 2017 |
Radiosensitizing effect of diosmetin on radioresistant lung cancer cells via Akt signaling pathway.
Topics: A549 Cells; Cell Line, Tumor; Cell Proliferation; Chromones; DNA Repair; Flavonoids; G1 Phase; Heter | 2017 |
Anti‑lung cancer effect of glucosamine by suppressing the phosphorylation of FOXO.
Topics: A549 Cells; Antineoplastic Agents; Butadienes; Cell Proliferation; Chromones; Epithelial Cells; Extr | 2017 |
Knockdown of CPEB4 expression suppresses cell migration and invasion via Akt pathway in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Chromones; Gene Knockdown Technique | 2018 |
Therapeutic efficacy of hydrogen‑rich saline alone and in combination with PI3K inhibitor in non‑small cell lung cancer.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Chromones; Heme Oxygenase-1; Humans; Hydrogen; Lung Neop | 2018 |
Vicenin-2 acts as a radiosensitizer of the non-small cell lung cancer by lowering Akt expression.
Topics: Apigenin; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survi | 2019 |
LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway.
Topics: Adult; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Prolifer | 2018 |
Structure Identification of ViceninII Extracted from
Topics: Antineoplastic Agents; Apigenin; Benzamides; Cell Line, Tumor; Cell Movement; Cell Survival; Chromon | 2019 |
ATAD2 expression increases [18F]Fluorodeoxyglucose uptake value in lung adenocarcinoma via AKT-GLUT1/HK2 pathway.
Topics: Adenocarcinoma of Lung; ATPases Associated with Diverse Cellular Activities; Cell Movement; Cell Pro | 2019 |
Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chromones; Cisplatin; Drug Resistance, | 2013 |
Akt1 enhances CA916798 expression through mTOR pathway.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Blotting, Western; Cell Line, Tumor; Chromones; DNA P | 2013 |
DIXDC1 increases the invasion and migration ability of non-small-cell lung cancer cells via the PI3K-AKT/AP-1 pathway.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromones; Fema | 2014 |
Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; | 2014 |
FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Bone Neoplasms; Breast Neoplasms; Cell Proliferatio | 2013 |
C-C chemokine receptor 5 on pulmonary mesenchymal cells promotes experimental metastasis via the induction of erythroid differentiation regulator 1.
Topics: Animals; CCR5 Receptor Antagonists; Cell Line, Tumor; Chromones; Coculture Techniques; Female; Gene | 2014 |
HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chromones; Cisplatin; Do | 2014 |
Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anthracyclines; Carcinoma, Non-Small-Cell Lung; Cell Line, T | 2014 |
Ran GTPase induces EMT and enhances invasion in non-small cell lung cancer cells through activation of PI3K-AKT pathway.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Enzyme Activation; Enzyme Inhibitors; E | 2013 |
Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; Chromones; Humans; Insulin- | 2014 |
The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporter | 2014 |
Sphingosine kinase 1 enhances the invasion and migration of non-small cell lung cancer cells via the AKT pathway.
Topics: Adaptor Proteins, Signal Transducing; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; C | 2015 |
Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus.
Topics: Adenoviridae; Animals; Apoptosis; Benzoquinones; Cell Line, Tumor; Cell Survival; Chromones; Enzyme | 2015 |
Quercetin Decreases Claudin-2 Expression Mediated by Up-Regulation of microRNA miR-16 in Lung Adenocarcinoma A549 Cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Butadienes; Cell Line, Tumor; Cell Proliferation; Chromones; | 2015 |
Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Line, Tumor | 2015 |
Novel dihydrobenzofuro[4,5-b][1,8]naphthyridin-6-one derivative, MHY-449, induces cell cycle arrest and apoptosis via the downregulation of Akt in human lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Benzofurans; Cell Cycle Checkpoints; Cell Line, Tumor; Chromones; | 2015 |
An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; Drug | 2016 |
Claudin-18 inhibits cell proliferation and motility mediated by inhibition of phosphorylation of PDK1 and Akt in human lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Anoikis; Cell Line, Tumor; Cell Membrane Permeability; Cell Movement; Cell Prolifera | 2016 |
FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Feedb | 2016 |
Repurposing ospemifene for potentiating an antigen-specific immune response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calmodulin; Cancer Vaccin | 2017 |
Pellino-1 promotes lung carcinogenesis via the stabilization of Slug and Snail through K63-mediated polyubiquitination.
Topics: A549 Cells; Animals; Cell Line, Tumor; Chromones; Down-Regulation; Epithelial-Mesenchymal Transition | 2017 |
Down-regulation of Claudin-2 Expression and Proliferation by Epigenetic Inhibitors in Human Lung Adenocarcinoma A549 Cells.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Azacitidine; Butyric Acid; Cell Proliferation; C | 2017 |
A genomic approach to identify molecular pathways associated with chemotherapy resistance.
Topics: Blotting, Western; Cell Death; Cell Line, Tumor; Chromones; Cisplatin; Docetaxel; Drug Resistance, N | 2008 |
Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway.
Topics: Adenocarcinoma; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Movement; Chrom | 2009 |
Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromones; Cyclin A; Cyclin-De | 2008 |
CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways.
Topics: Blotting, Western; Cell Line, Tumor; Chemokine CCL5; Chromones; Enzyme-Linked Immunosorbent Assay; F | 2009 |
Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines.
Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Chromones; Cisplatin; Cyclooxygenase In | 2009 |
Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung.
Topics: Adenocarcinoma; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Cell | 2009 |
[Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma | 2008 |
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.
Topics: Benzodioxoles; Cell Line, Tumor; Cell Movement; Chromones; Focal Adhesion Protein-Tyrosine Kinases; | 2009 |
Induction of apoptosis in human lung carcinoma cells by the water extract of Panax notoginseng is associated with the activation of caspase-3 through downregulation of Akt.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumo | 2009 |
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; | 2009 |
Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Chromones; Cyclin-Dependent Kinase Inhibitor | 2009 |
Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells.
Topics: Apoptosis; Blotting, Western; Carcinoid Tumor; Cell Line, Tumor; Cell Proliferation; Chromones; Dose | 2009 |
mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells.
Topics: AC133 Antigen; Antigens, CD; Cell Line, Tumor; Chromones; Colorectal Neoplasms; Down-Regulation; Gly | 2009 |
Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Down-Regulation | 2011 |
Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Baculoviral IAP Repeat-Containing 3 Protein; Base Sequence | 2010 |
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Cluster Analysis | 2011 |
Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Benzoquinones; Biomarkers, Tumor; Blotting, Wes | 2011 |
Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell | 2011 |
miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A.
Topics: Carcinoma, Non-Small-Cell Lung; Chromones; Down-Regulation; Doxorubicin; Humans; Lung Neoplasms; Mic | 2012 |
Raf and PI3K are the molecular targets for the anti-metastatic effect of luteolin.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chromones; Ind | 2013 |
[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chromones; Drug | 2012 |
Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells.
Topics: Benzoquinones; Breast Neoplasms; Cell Proliferation; Chromones; Diterpenes; Drug Synergism; Female; | 2013 |
Insulin-like growth factor-I inhibits cell growth in the a549 non-small lung cancer cell line.
Topics: Adenocarcinoma; Apoptosis; Cell Division; Chromones; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; | 2002 |
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Division; Cell Movement; Cell Size; | 2002 |
Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
Topics: Alleles; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Car | 2002 |
Cell adhesion to the extracellular matrix protein fibronectin modulates radiation-dependent G2 phase arrest involving integrin-linked kinase (ILK) and glycogen synthase kinase-3beta (GSK-3beta) in vitro.
Topics: Annexin A5; Apoptosis; Cell Adhesion; Cell Line; Chromones; Enzyme Inhibitors; Extracellular Matrix; | 2003 |
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway.
Topics: Antineoplastic Agents; Apoptosis; Chromones; Cisplatin; Female; Fibronectins; Humans; Inositol Phosp | 2004 |
Distinctive regulation and function of PI 3K/Akt and MAPKs in doxorubicin-induced apoptosis of human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Annexin A5; Apoptosis; Blotting, Western; Carrier Proteins; Caspases; Cell Line, Tum | 2004 |
Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Survival; Chromon | 2004 |
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Growth Processe | 2005 |
Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Topics: Adenoviridae; Animals; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspase 3; Casp | 2005 |
A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8.
Topics: Cell Line, Tumor; Cell Movement; Chromones; Cytoskeletal Proteins; Enzyme Inhibitors; Humans; Immuno | 2005 |
Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Cell Adhesion; Cell Survival; Chromones; D | 2005 |
Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways.
Topics: Anticarcinogenic Agents; Butadienes; Cell Line, Tumor; Cell Movement; Chromones; Dose-Response Relat | 2005 |
Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis.
Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Breast Neoplasms; Butadienes; Carcinoma, Non- | 2005 |
Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Chromones; Enzyme Inhibitors; Histone Deacetylas | 2005 |
The targeting of phosphoinositide-3 kinase attenuates pulmonary metastatic tumor growth following laparotomy.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Cell Division; Chromones; Enzyme Inhibitors; | 2006 |
Inhibitors of the PI3-kinase/Akt pathway induce mitotic catastrophe in non-small cell lung cancer cells.
Topics: Androstadienes; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell S | 2006 |
LY294002, an inhibitor of PI-3K, enhances heat sensitivity independently of p53 status in human lung cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Chromones; DNA; DNA-Binding Proteins; Heat Shock Transcr | 2006 |
Effects of GM-CSF and M-CSF on tumor progression of lung cancer: roles of MEK1/ERK and AKT/PKB pathways.
Topics: Adenocarcinoma; Cell Death; Cell Line, Tumor; Chromones; Disease Progression; Enzyme Activation; Ext | 2006 |
Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation.
Topics: Antineoplastic Agents; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; Enzyme Inhibitors; | 2006 |
Dexamethasone inhibits paclitaxel-induced cytotoxic activity through retinoblastoma protein dephosphorylation in non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Chromone | 2007 |
Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
Topics: Adenocarcinoma, Follicular; Animals; Apoptosis; Caspase 3; Cell Movement; Cell Proliferation; Chromo | 2007 |
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalysis; Cell Cycle; Cell Death; Cell Extra | 2008 |
Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Drug Screeni | 2008 |
In vivo and in vitro studies of anticancer actions of alpha-TEA for human prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Li | 2008 |
Combination of PTEN and gamma-ionizing radiation enhances cell death and G(2)/M arrest through regulation of AKT activity and p21 induction in non-small-cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Death; Ce | 2008 |
Constitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin.
Topics: Antineoplastic Agents; Apoptosis; Butadienes; Carcinoma, Small Cell; Cell Line, Tumor; Chromones; Ci | 2008 |
The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway.
Topics: Androstadienes; Carcinoma, Small Cell; Cell Adhesion; Cell Division; Cell Survival; Chromones; Human | 1998 |
Requirement of phosphatidylinositol 3-kinase activity for bradykinin stimulation of NF-kappaB activation in cultured human epithelial cells.
Topics: Adenocarcinoma; Androstadienes; Bradykinin; Cells, Cultured; Chromones; Enzyme Inhibitors; Epithelia | 1999 |
Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Survival; Chromones; Drug Screening Assays, Antitumo | 2001 |